Core Viewpoint - The 11th batch of national organized drug procurement is set to optimize rules focusing on "stabilizing clinical use, ensuring quality, preventing collusion, and countering excessive competition" Group 1: Clinical Stability and Quality Assurance - A total of 46,000 medical institutions participated in this procurement, allowing them to report brands based on clinical usage habits [1] - Special attention is given to the supply of pediatric medications, with price adjustments for small-sized oral solutions and injectable forms suitable for children [1] Group 2: Quality Control and Bidding Requirements - The procurement process imposes higher quality control standards, requiring bidders or their contracted manufacturers to have at least 2 years of production experience for similar dosage forms [3] - Preference will be given to enterprises recognized for clinical use and stable quality [3] - Measures to prevent collusion have been enhanced, and bidders must commit to pricing not lower than their costs; those bidding below 50% of the average entry price must justify their pricing [3] Group 3: Execution of Selected Results - Selected enterprises are designated as the primary responsible parties for supply assurance, required to respond promptly to medical institution orders and complete deliveries [5] - Medical institutions are expected to prioritize the procurement of selected products and adhere to agreed purchasing volumes and timely payment obligations [5]

Core Viewpoint - The 11th batch of national drug centralized procurement will take place on October 27, 2025, involving 55 drug varieties and over 400 participating companies [2][3]. Group 1: Procurement Process - The procurement process includes a pre-inspection of application materials starting at 7:00 AM, followed by material acceptance from 7:30 AM to 10:30 AM [2]. - The new procurement rules emphasize quality and competition, moving away from solely relying on the lowest bid as the price control reference [3]. Group 2: Competitive Landscape - Nine drug varieties have more than 20 competing companies, indicating intense competition, with over half of these companies likely to be eliminated [4]. - The most competitive drug is theophylline injection, with 48 companies bidding, and a projected market size of 650 million yuan in 2024 [5]. Group 3: Drug Specifics - Cefazolin injection and famotidine injection follow closely with 41 and 38 bidding companies, respectively, with market sizes of approximately 2.6 billion yuan and 1.63 billion yuan [5]. - The procurement process introduces a "revival" opportunity for non-selected companies if they can accept the winning bid price [6]. Group 4: Quality Assurance - The National Medical Insurance Administration has set higher quality assurance requirements, mandating at least two years of production experience for bidding companies [6].

Core Points - The 11th batch of national organized drug procurement was held in Shanghai on October 27, involving 55 drug varieties across various therapeutic areas including anti-infection, anti-tumor, asthma, diabetes, cardiovascular, and neurological drugs [2][9] - The procurement process introduced new mechanisms such as "revival for non-selected" opportunities to encourage more companies to participate at suitable prices, extending the bidding time compared to previous batches [9][10] - The procurement emphasizes principles of maintaining clinical stability, ensuring quality, preventing excessive competition, and avoiding collusion among related companies [10][11] Group 1: Procurement Details - The procurement involved 55 drug varieties and was conducted with a focus on transparency and public engagement, including online explanations of selection rules for medical institutions [11] - Since 2018, 10 batches of drug procurement have been conducted, covering 435 drug types and nearly 800 pharmaceutical companies, with over 2000 representative products involved [9][10] - The bidding process was structured to allow medical institutions to report quantities either by generic name or specific brand, with 77% of the 46,000 institutions reporting by brand [10] Group 2: Competitive Landscape - The average number of companies bidding per drug variety was 14, indicating a competitive environment, although some drugs had significantly more bidders, leading to intense competition [11][13] - The National Medical Insurance Administration issued a warning in August for companies to conduct cost-benefit analyses and maintain rational pricing strategies in light of high competition [13]

Core Viewpoint - The article discusses the 11th batch of national organized drug procurement, highlighting its focus on transparency, quality assurance, and competitive pricing mechanisms in the pharmaceutical industry [3][10][13]. Group 1: Procurement Details - The 11th batch of drug procurement includes 55 varieties, covering treatment areas such as anti-infection, anti-tumor, asthma, diabetes, cardiovascular, and neurological drugs [3]. - The procurement process involved a two-round revival mechanism, allowing more companies to qualify, which is expected to extend the bidding time compared to previous batches [10]. - Since 2018, the national level has conducted 10 batches of drug procurement, covering 435 drugs and nearly 800 companies, involving over 2,000 representative products [10]. Group 2: Principles and Optimizations - The procurement adheres to principles of stabilizing clinical use, ensuring quality, preventing excessive competition, and avoiding collusion [10][11]. - The reporting method for medical institutions has been optimized, allowing them to report either by generic name or specific brand, with 77% of the 46,000 institutions reporting by brand [10]. - Quality standards have been raised, requiring that production lines have no GMP violations in the past two years [10]. Group 3: Transparency and Competition - A significant highlight of this procurement is its emphasis on transparency, with the procurement office publicly explaining the selection rules and conducting online sessions for medical institutions [13]. - On average, 14 companies have applied for each variety, indicating that most companies are expected to qualify, although competition may be fierce for some varieties with a high number of bidders [13][15]. - The National Medical Insurance Administration issued a warning in August for companies to conduct cost-benefit analyses and maintain rational pricing in light of high competition [15].

Core Viewpoint - The 11th batch of national organized drug procurement has introduced new rules to ensure quality and prevent price undercutting, with a focus on maintaining clinical stability and quality assurance [4][8]. Group 1: Procurement Process - The 11th batch of drug procurement involved 55 varieties, with over 400 participating companies [3]. - The submission process included a pre-check and security check for companies, with material acceptance starting at 7:30 AM and ending at 10:30 AM [3]. Group 2: New Pricing Rules - The new pricing mechanism sets a "reference price" as the higher of 50% of the average "unit comparable price" of valid applicants or the lowest "unit comparable price," preventing extreme low bids from disrupting normal pricing [4]. - All bidding companies must commit to not pricing below their cost and must provide a rationale for any low bids to address quality concerns [4]. Group 3: Competitive Landscape - Nine varieties in the procurement have over 20 competing companies, indicating that more than half will not be selected based on a maximum of 10 entrants [6]. - The most competitive product is the Theophylline injection, with 48 bidding companies, and a market size of 650 million yuan in 2024 [7]. - Other competitive products include Cefazolin injection with 41 bidders and Famotidine injection with 38 bidders, with market sizes of approximately 2.6 billion yuan and 1.63 billion yuan respectively [7]. Group 4: Quality Assurance Measures - The National Medical Insurance Administration has raised quality assurance standards, requiring bidders to have at least two years of production experience and compliance with GMP standards [8]. - These measures aim to mitigate quality risks associated with inexperienced manufacturers and ensure the reliability of selected drugs [8]. Group 5: New Opportunities for Non-Selected Companies - The procurement process now includes a "revival" opportunity for non-selected companies if they can accept the winning bid price, addressing high demand from medical institutions [7].

Core Points - The 11th batch of national organized drug procurement will take place on October 27, 2025, involving 55 drug varieties and over 400 participating companies [1] - The new procurement rules emphasize quality assurance and prevent price undercutting, with a new "anchor" price set at the higher of 50% of the average comparable price of valid applicants or the lowest comparable price [2] - There is intense competition for certain drug varieties, with nine varieties having more than 20 competing companies, indicating that over half will not qualify [3] Group 1 - The most competitive drug is theophylline injection, with 48 companies bidding, and a projected market size of 650 million yuan in 2024 [4] - Other highly competitive drugs include cefazolin injection with 41 bidders and famotidine injection with 38 bidders, with market sizes of approximately 2.6 billion yuan and 1.63 billion yuan respectively [4] - The procurement process introduces a "revival" opportunity for non-selected companies if they can accept the winning bid price [4] Group 2 - The National Medical Insurance Administration has set higher quality assurance requirements for bidding companies, mandating at least two years of production experience and compliance with GMP standards [5]

Core Points - The 11th batch of national drug centralized procurement took place on October 27, involving 55 drug varieties across various therapeutic areas including anti-infection, anti-tumor, asthma, diabetes, cardiovascular, and neurological drugs [1][8] - The procurement process has introduced a "two-round revival" mechanism, which will extend the time required for the bidding compared to previous batches [8] - The procurement aims to maintain clinical stability, ensure quality, prevent excessive competition, and avoid collusion among related companies [11] Group 1: Procurement Process - The bidding process began with a pre-inspection of application materials and company registration starting at 7:00 AM, followed by the acceptance of application materials from 7:30 AM to 10:30 AM [1][5] - The procurement office has publicly explained the selection rules for drug varieties and provided detailed guidance for medical institutions on reporting requirements [12] Group 2: Competitive Landscape - Since 2018, the national level has conducted 10 batches of drug procurement, covering 435 drug varieties and nearly 800 pharmaceutical companies, involving over 2,000 representative products [11] - The average number of companies applying for each drug variety in this batch is 14, indicating a competitive environment, especially for certain products with a high number of bidders [12] Group 3: Quality and Compliance - The procurement process has raised quality standards by requiring that production lines have no GMP violations in the past two years [11] - Measures have been implemented to prevent collusion among companies with related interests, treating them as a single entity for bidding purposes [11]

Core Insights - The 11th batch of national organized drug procurement will involve 55 varieties, with over 400 companies participating in the bidding process [1] - The new procurement rules emphasize quality assurance and prevent price undercutting, with a new "anchor" price system established [1][4] - There is intense competition for certain drug varieties, with some having over 20 bidding companies, indicating a high likelihood of many companies being eliminated [2][3] Group 1: Procurement Process - The procurement event took place on October 27, 2025, with a structured process for material submission and company registration [1] - The submission process included pre-checks and security checks, with a strict timeline for material acceptance [1] Group 2: Competition Analysis - Nine drug varieties have more than 20 bidding companies, suggesting that over half of these companies will not be selected [2] - The most competitive drug is theophylline injection, with 48 bidding companies, followed by cefazolin injection and famotidine injection with 41 and 38 companies respectively [3] Group 3: Market Insights - The domestic market size for theophylline injection is projected to be 650 million yuan in 2024 [3] - Cefazolin injection has a stable market size of approximately 2.6 billion yuan from 2022 to 2024 [3] - Famotidine injection's sales for 2024 are estimated at 1.63 billion yuan, with 616 million yuan in sales for the first half of 2025 [3] Group 4: Quality Assurance - The National Medical Insurance Administration has set higher quality assurance standards for bidding companies, requiring at least two years of production experience and compliance with GMP [4] - The new rules aim to mitigate quality risks associated with inexperienced manufacturers [4]

Core Viewpoint - The eleventh batch of national organized drug procurement has commenced, involving over 400 companies and covering 55 drug varieties, with a focus on quality control and fair competition in pricing [1] Group 1: Procurement Details - The procurement process started at 7:30 AM in Qingpu District, Shanghai, with public disclosure of application information at 10:30 AM [1] - The procurement includes significant products such as cefoperazone injection and dapagliflozin oral sustained-release formulation, projected to achieve sales in the billions for 2024 [1] - Major pharmaceutical companies like Heng Rui Medicine, Qilu Pharmaceutical, and AstraZeneca are participating with multiple products [1] Group 2: Procurement Rules - The new procurement rules emphasize "stabilizing clinical use, ensuring quality, preventing internal competition, and avoiding collusion" [1] - For the first time, medical institutions are allowed to report quantities based on brand names, enhancing the focus on quality control [1] - Each participating company must commit to pricing no lower than their costs, with lower-priced bids requiring a justification for their pricing to promote healthy market competition [1]

"赛能赶上黄金了，一天一个价。" "赛能是不是要停产了，哪里的医院还能开？" 近日，红星资本局注意到，硫酸羟氯喹片原研药赛能缺货、涨价的消息在社交平台上传播。 资料配图 图据视觉中国 原研药赛能价格翻倍 多地线下药房缺货 近日，家住广东的刘女士（化名）向红星资本局表示，今年她因为备孕查出身体免疫系统问题，医生开了一款硫酸羟氯喹片，但吃了一段时间 发现指标还在增加，便在医生的建议下换成了原研药赛能。 "（当时）医院只能开那一款，我已经两个月没在医院开药了。"刘女士称，她主要在电商平台买药，一盒10片装的赛能够吃5天。但最近，她突 然发现原本四五十元一盒的药已经涨价至八九十元，"吃不起了"。刘女士甚至开始将目光投向较为便宜的海外版赛能。 同样面临着缺药焦虑的还有浙江的吴女士（化名）。吴女士告诉红星资本局，她发现赛能在国庆后突然涨价了，每盒从40元涨到了60元，于是 立即在网上下单了40盒，买完两天后发现又涨价至80元，"一天一个价"。她表示，作为一款长期要吃的药，一般不能随意更换或停药，但如果 之后价格继续涨也没有办法，只能换药。 【原研进口】赛能 硫酸羟氯喹片 ¥300.00 0.2g*10片/盒 共5件 不支 ...